The London South East, Investing Matters Podcast - Episode 5 featuring Annabel Brodie-Smith, the Communications Director at The AIC is now LIVE. Listen here.

Less Ads, More Data, More Tools Register for FREE

PRESS: Doubts Raised Over AstraZeneca-Oxford Vaccine Data - FT

Thu, 26th Nov 2020 06:55

(Alliance News) - Concerns are increasing over the way Oxford University and AstraZeneca PLC have handled the early readout from trials of their coronavirus vaccine candidate, the Financial Times reported on Wednesday.

https://www.ft.com/content/4583fbf8-b47c-4e78-8253-22efcfa4903a

The results were hailed a success for showing an average efficacy of 70%, a figure reached by pooling the results from cohorts on two different dosing regimens.

AstraZeneca on Monday said one dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart. Another dosing regimen showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens resulted in an average efficacy of 70%.

But on Tuesday, Moncef Slaoui, the head of Operation Warp Speed, the US government's funding programme for vaccine development, disclosed that the subgroup that scored 90% was limited to people aged 55 or below, a demographic with lower risk of developing severe Covid-19, FT reported.

Oxford and AstraZeneca did not disclose the age breakdown on Monday, when results were released.

AstraZeneca shares closed 2.4% lower on Wednesday in London at 7,810.00 pence each. The stock is down 6.0% so far this week.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News

TOP NEWS: New AstraZeneca vaccine results show strong effect on Covid

TOP NEWS: New AstraZeneca vaccine results show strong effect on Covid

13 Jan 22 10:54

LONDON BRIEFING: AIM giant ASOS to move to London Main Market

LONDON BRIEFING: AIM giant ASOS to move to London Main Market

13 Jan 22 08:24

TOP NEWS: US buys 500,000 doses of Astra's Evusheld Covid antibody

TOP NEWS: US buys 500,000 doses of Astra's Evusheld Covid antibody

12 Jan 22 20:18

TOP NEWS: AstraZeneca's subsidiary enters agreement with Neurimmune

TOP NEWS: AstraZeneca's subsidiary enters agreement with Neurimmune

7 Jan 22 09:47

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.